Cellular Biomedicine Group Inc. (NASDAQ:CBMG) has posted results for the last fiscal year, recording EPS of $-2.14. For this year, EPS is anticipated to grow -23.20% over the preceding year, while next year?s EPS is predicted to increase -2.80%.
The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
Recently, Cellular Biomedicine Group Inc. (NASDAQ:CBMG) reported that for the previous five years, EPS at Cellular Biomedicine Group Inc. has increased -32.90%, while rise sales have surged 77.60% over the same period.
Shares of Cellular Biomedicine Group Inc. are now trading at $7.95, giving it market cap of $100.81M. Over the last 12 months, shares of Cellular Biomedicine Group Inc. have risen to maximum of $-49.33% and declined to a minimum of $57.43%.
The stock’s beta, which measures volatility, is 3.05. For the purpose of clarity, note that a beta of less than 1 implies that a stock is less volatile versus the overall market, while a beta over 1 indicates a stock is more volatile over the market.
Cellular Biomedicine Group Inc. shows 20-Day Simple Moving Average of $2.32% and 50-Day Simple Moving Average of $-18.94%. The 200-Day SMA is $-35.55%.
The stock’s weekly performance is 30.33% while its monthly performance is -25.70%. Year-to-date the equity has moved -39.31% compared to a performance of -47.66% over the preceding 12 months.
Cellular Biomedicine Group Inc. has witnessed 0.00% insider transactions, showing insider ownership of 1.20%. That compares to 9.90% ownership by institutional investors after -4.78% institutional transactions.
Return on investments in Cellular Biomedicine Group Inc. for the last 12 months is -43.10%, while return on assets for the equivalent period is -41.20%. Return on equity for the previous 12 months, on the other hand, is -42.60%.
Cellular Biomedicine Group Inc. has RSI (Relative Strength Index) of 49.41.
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the Company’s Board of Directors (the “Board”) has approved a new stock repurchase program granting the company authority to repurchase up to $10 million in common shares (the “2017 Stock Repurchase Program”) through open market purchases pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and in accordance with Rule 10b-18 of the Exchange Act.